Esperion presents stroke reduction data for NEXLETOL at cardiology conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
March 30, 2026 8:00 AM EDTÂ Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo
Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with Autoimmune or Inflammatory Diseases (AIID) Similarly to Those Without AIID
ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of two post-hoc analyses from CLEAR Outcomes focused on risk of ischemic stroke and risk of major adverse cardiovascular events (MACE) in patients with autoimmune or inflammatory diseases. These data were presented as moderated poster... More
